[go: up one dir, main page]

SG170020A1 - The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron - Google Patents

The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Info

Publication number
SG170020A1
SG170020A1 SG201101266-3A SG2011012663A SG170020A1 SG 170020 A1 SG170020 A1 SG 170020A1 SG 2011012663 A SG2011012663 A SG 2011012663A SG 170020 A1 SG170020 A1 SG 170020A1
Authority
SG
Singapore
Prior art keywords
iron
deferiprone
treat
methods
friedreich ataxia
Prior art date
Application number
SG201101266-3A
Other languages
English (en)
Inventor
Arnold Munnich
Michael Spino
Ioav Cabantchik
Original Assignee
Arnold Munnich
Michael Spino
Ioav Cabantchik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arnold Munnich, Michael Spino, Ioav Cabantchik filed Critical Arnold Munnich
Publication of SG170020A1 publication Critical patent/SG170020A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201101266-3A 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron SG170020A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77532006P 2006-02-22 2006-02-22

Publications (1)

Publication Number Publication Date
SG170020A1 true SG170020A1 (en) 2011-04-29

Family

ID=38436879

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201101266-3A SG170020A1 (en) 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Country Status (24)

Country Link
US (3) US20090023784A1 (es)
EP (1) EP1991225B1 (es)
JP (1) JP5730466B2 (es)
KR (1) KR20080104329A (es)
CN (1) CN101420954A (es)
AU (1) AU2007219009B2 (es)
BR (1) BRPI0708211A2 (es)
CA (1) CA2642778A1 (es)
DK (1) DK1991225T3 (es)
ES (1) ES2441065T3 (es)
IL (1) IL193598A (es)
MA (1) MA30266B1 (es)
MX (1) MX2008010824A (es)
MY (1) MY151412A (es)
NZ (1) NZ570730A (es)
PL (1) PL1991225T3 (es)
PT (1) PT1991225E (es)
RS (1) RS53225B (es)
RU (1) RU2008137604A (es)
SG (1) SG170020A1 (es)
SI (1) SI1991225T1 (es)
TN (1) TNSN08338A1 (es)
UA (1) UA95099C2 (es)
WO (1) WO2007095728A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008137604A (ru) * 2006-02-22 2010-03-27 Арнольд МЮННИК (FR) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа
CA2627529A1 (en) 2007-03-28 2008-09-28 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
BRPI0822206B8 (pt) * 2008-04-25 2021-05-25 Apotex Tech Inc formulação líquida para deferiprona com um sabor agradável.
AP2011005843A0 (en) 2009-01-26 2011-08-31 Joshua Lawrence Dunaief Use of deferiprone for treatment and prevention ofiron-related eye disorders.
EP2448922B1 (en) 2009-07-03 2014-08-20 Apotex Technologies Inc. Fluorinated derivatives of 3-hydroxypyridin-4-ones
CN102573842A (zh) 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
CA2809747C (en) 2010-08-30 2018-05-01 Roberto Testi Compositions and methods for treating friedreich's ataxia with interferon gamma
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
WO2013139931A1 (en) * 2012-03-21 2013-09-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
DK3684344T3 (da) 2017-10-25 2025-08-04 Chiesi Farm Spa Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
WO2025006917A1 (en) * 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Uses of iron chelators for treating stuttering

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
WO2004006856A2 (en) * 2002-07-12 2004-01-22 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
RU2008137604A (ru) * 2006-02-22 2010-03-27 Арнольд МЮННИК (FR) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа

Also Published As

Publication number Publication date
UA95099C2 (ru) 2011-07-11
EP1991225A1 (en) 2008-11-19
KR20080104329A (ko) 2008-12-02
RS53225B (sr) 2014-08-29
BRPI0708211A2 (pt) 2011-05-17
WO2007095728A1 (en) 2007-08-30
CN101420954A (zh) 2009-04-29
CA2642778A1 (en) 2007-08-30
MX2008010824A (es) 2009-06-08
EP1991225A4 (en) 2009-07-29
ES2441065T3 (es) 2014-01-31
EP1991225B1 (en) 2013-11-06
MY151412A (en) 2014-05-30
MA30266B1 (fr) 2009-03-02
NZ570730A (en) 2013-05-31
TNSN08338A1 (en) 2009-12-29
AU2007219009A1 (en) 2007-08-30
PL1991225T3 (pl) 2014-04-30
SI1991225T1 (sl) 2014-02-28
US20130190365A1 (en) 2013-07-25
DK1991225T3 (da) 2013-12-16
JP2009527506A (ja) 2009-07-30
JP5730466B2 (ja) 2015-06-10
PT1991225E (pt) 2014-02-13
IL193598A (en) 2012-08-30
RU2008137604A (ru) 2010-03-27
IL193598A0 (en) 2009-08-03
US20070197649A1 (en) 2007-08-23
US20090023784A1 (en) 2009-01-22
AU2007219009B2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
SG170020A1 (en) The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
NZ595629A (en) Methods for preventing and/or treating lysosomal storage disorders
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
NZ596154A (en) Cyclic compound having substituted phenyl group
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
MX2009012752A (es) Carbamoil-ciclohexanos para el tratamiento de la mania aguda.
IL175259A0 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
NO20065662L (no) Esterlinkede makrolider nyttige for behandlingen av mikrobielle infeksjoner
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
EA201170970A1 (ru) Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
TN2010000249A1 (en) New medical use of 3-(2,2,2-trimethylhydrazinium ) propionate salts
CY1114714T1 (el) Η χρηση δεφεριπρονης και μεθοδοι για την θεραπεια και/ή προληψη της αταξιας friedreich που προκυπτει απο ενδοκυτταρικη κακη διαχειριση σιδηρου
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
WO2011044434A3 (en) A composition and a method of treating cns disorders and hyperpigmentation
MY144229A (en) Pyridazine derivatives and their use as therapeutic agents
EA201490173A1 (ru) Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции
CN204709113U (zh) 医用约束带
RU2004131017A (ru) Способ лечения вич-инфицированных больных